[Sigh] [Sigh]_老虎社区_美港股上老虎 - 老虎社区

[Sigh] [Sigh]

@财见：波士顿科学向先瑞达医疗发起部分要约

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":629740840,"tweetId":"629740840","gmtCreate":1670890140081,"gmtModify":1670890142222,"author":{"id":3578126421270532,"idStr":"3578126421270532","authorId":3578126421270532,"authorIdStr":"3578126421270532","name":"Cccccccccccc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><span>[Sigh]&nbsp;</span><span>[Sigh]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[Sigh]&nbsp;</span><span>[Sigh]&nbsp;</span></p></body></html>","text":"[Sigh] [Sigh]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/629740840","repostId":629735663,"repostType":1,"repost":{"magic":2,"id":629735663,"tweetId":"629735663","gmtCreate":1670844262052,"gmtModify":1670844277506,"author":{"id":4100392628064900,"idStr":"4100392628064900","authorId":4100392628064900,"authorIdStr":"4100392628064900","name":"财见","avatar":"https://static.tigerbbs.com/dfecb1713c6fef32fde051255c4518f3","vip":5,"userType":5,"introduction":"美通社1954年开创了企业新闻稿发布行业的先河，于2016年成为Cision 旗下公司。","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":737,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"波士顿科学向先瑞达医疗发起部分要约","html":"<html><head></head><body><p>波士顿科学公司与先瑞达医疗科技控股有限公司宣布，波士顿科学将发起部分要约，以收购先瑞达最多不超过65%股份的多数股权，先瑞达是一家中国医疗科技企业，针对各类介入手术提供解决方案。该交易拟议价格为每股20港元，按当前汇率计算，65%股权的现金对价约为5.23亿美元。先瑞达是创新医疗解决方案领域的领军企业，提供包括用于治疗血管和其他疾病的药物涂层球囊(DCB)在内的产品组合。(医药健闻)</p></body></html>","htmlText":"<html><head></head><body><p>波士顿科学公司与先瑞达医疗科技控股有限公司宣布，波士顿科学将发起部分要约，以收购先瑞达最多不超过65%股份的多数股权，先瑞达是一家中国医疗科技企业，针对各类介入手术提供解决方案。该交易拟议价格为每股20港元，按当前汇率计算，65%股权的现金对价约为5.23亿美元。先瑞达是创新医疗解决方案领域的领军企业，提供包括用于治疗血管和其他疾病的药物涂层球囊(DCB)在内的产品组合。(医药健闻)</p></body></html>","text":"波士顿科学公司与先瑞达医疗科技控股有限公司宣布，波士顿科学将发起部分要约，以收购先瑞达最多不超过65%股份的多数股权，先瑞达是一家中国医疗科技企业，针对各类介入手术提供解决方案。该交易拟议价格为每股20港元，按当前汇率计算，65%股权的现金对价约为5.23亿美元。先瑞达是创新医疗解决方案领域的领军企业，提供包括用于治疗血管和其他疾病的药物涂层球囊(DCB)在内的产品组合。(医药健闻)","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/629735663","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["BSX","06669"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":357,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":272,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/629740840"}